PMID- 29425589
OWN - NLM
STAT- MEDLINE
DCOM- 20180726
LR  - 20180726
IS  - 1875-5364 (Electronic)
IS  - 1875-5364 (Linking)
VI  - 16
IP  - 1
DP  - 2018 Jan
TI  - Puerarin attenuates angiotensin II-induced cardiac fibroblast proliferation via 
      the promotion of catalase activity and the inhibition of hydrogen 
      peroxide-dependent Rac-1 activation.
PG  - 41-52
LID - S1875-5364(18)30028-1 [pii]
LID - 10.1016/S1875-5364(18)30028-1 [doi]
AB  - The aims of the present study were to evaluate the effects of puerarin on 
      angiotensin II-induced cardiac fibroblast proliferation and to explore the 
      molecular mechanisms of action. Considering the role of H(2)O(2) in nicotinamide 
      adenine dinucleotide phosphate (NADPH) oxidase activation, we hypothesized that 
      modulating catalase activity would be a potential target in regulating the 
      redox-sensitive pathways. Our results showed that the activation of Rac1 was 
      dependent on the levels of intracellular H(2)O(2). Puerarin blocked the 
      phosphorylation of extracellular regulated protein kinases (ERK)1/2, abolished 
      activator protein (AP)-1 binding activity, and eventually attenuated cardiac 
      fibroblast proliferation through the inhibition of H(2)O(2)-dependent Rac1 
      activation. Further studies revealed that angiotensin II treatment resulted in 
      decreased catalase protein expression and enzyme activity, which was disrupted by 
      puerarin via the upregulation of catalase protein expression at the 
      transcriptional level and the prolonged protein degradation. These findings 
      indicated that the anti-proliferation mechanism of puerarin was mainly through 
      blocking angiontensin II-triggered downregulation of catalase expression and 
      H(2)O(2)-dependent Rac1 activation.
CI  - Copyright (c) 2018 China Pharmaceutical University. Published by Elsevier B.V. All 
      rights reserved.
FAU - Chen, Gang
AU  - Chen G
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing 100020, China.
FAU - Pan, Shi-Fen
AU  - Pan SF
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing 100020, China.
FAU - Cui, Xiang-Li
AU  - Cui XL
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing 100020, China.
FAU - Liu, Li-Hong
AU  - Liu LH
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing 100020, China. Electronic address: hongllh@126.com.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin J Nat Med
JT  - Chinese journal of natural medicines
JID - 101504416
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Isoflavones)
RN  - 0 (Neuropeptides)
RN  - 0 (Rac1 protein, mouse)
RN  - 0 (Transcription Factor AP-1)
RN  - 11128-99-7 (Angiotensin II)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - EC 1.11.1.6 (Catalase)
RN  - EC 1.6.3.- (NADPH Oxidases)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - EC 3.6.5.2 (rac1 GTP-Binding Protein)
RN  - Z9W8997416 (puerarin)
SB  - IM
MH  - Angiotensin II/pharmacology
MH  - Angiotensin II Type 1 Receptor Blockers/pharmacology
MH  - Animals
MH  - Animals, Newborn
MH  - Catalase/genetics/*metabolism
MH  - Cell Proliferation/*drug effects
MH  - Cells, Cultured
MH  - Extracellular Signal-Regulated MAP Kinases/antagonists & inhibitors/metabolism
MH  - Fibroblasts
MH  - Gene Expression Regulation/drug effects
MH  - Heart/*drug effects
MH  - Hydrogen Peroxide/*metabolism/pharmacology
MH  - Isoflavones/*pharmacology
MH  - Mice
MH  - Myocardium/cytology/enzymology/metabolism
MH  - NADPH Oxidases/antagonists & inhibitors/metabolism
MH  - Neuropeptides/*metabolism
MH  - Signal Transduction/drug effects
MH  - Transcription Factor AP-1/antagonists & inhibitors/metabolism
MH  - Transcriptional Activation/drug effects
MH  - rac1 GTP-Binding Protein/*metabolism
OTO - NOTNLM
OT  - Angiontensin II
OT  - Catalase
OT  - Hydrogen peroxide
OT  - Puerarin
EDAT- 2018/02/10 06:00
MHDA- 2018/07/27 06:00
CRDT- 2018/02/10 06:00
PHST- 2017/05/11 00:00 [received]
PHST- 2018/02/10 06:00 [entrez]
PHST- 2018/02/10 06:00 [pubmed]
PHST- 2018/07/27 06:00 [medline]
AID - S1875-5364(18)30028-1 [pii]
AID - 10.1016/S1875-5364(18)30028-1 [doi]
PST - ppublish
SO  - Chin J Nat Med. 2018 Jan;16(1):41-52. doi: 10.1016/S1875-5364(18)30028-1.